To examine B7H6 expression on AML and melanoma as a representative solid tumor target for CAR T therapy, we screened a panel of eighteen patient-derived AML samples and three primary melanoma samples (MZ12, MZ9, Ma-mel86b) as well as melanoma cell lines (A375, 526 mel, DAJU) and additionally U87 (glioblastoma) and HEK 293T (epithelial carcinoma) by real-time RT-PCR and flow cytometry (Figure 2A,B). The gene discussed is NCR3LG1; the disease is carcinoma.